Last reviewed · How we verify
Aceon (PERINDOPRIL ARGININE)
At a glance
| Generic name | PERINDOPRIL ARGININE |
|---|---|
| Sponsor | Symplmed Pharms Llc |
| Drug class | Angiotensin Converting Enzyme Inhibitor |
| Target | Angiotensin-converting enzyme |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1993 |
Approved indications
- Hypertensive disorder
- Myocardial Infarction Prevention
Common side effects
- Edema
- Cough
- Headache
- Dizziness
- Hyperkalemia
- Peripheral edema
- Back pain
- Nausea
- Diarrhea
- Rash
Drug interactions
- spironolactone
- triamterene
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension. (PHASE3)
- Observational Cohort Study Evaluating the Effectiveness of an Educational Program (NGAYDAUTIEN) in Combination With Perindopril and Amlodipine Single-Pill Combination in Hypertensive Patients naïve of Antihypertensive Treatments.
- Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET)
- Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions (PHASE1)
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients (NA)
- Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia (PHASE3)
- Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |